Patents by Inventor Alexandra Briner Crawley
Alexandra Briner Crawley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11981940Abstract: Compositions and methods comprising novel deaminase polypeptides for targeted editing of nucleic acids are provided. Compositions comprise deaminase polypeptides. Also provided are fusion proteins comprising a DNA-binding polypeptide and a deaminase of the invention. The fusion proteins include RNA-guided nucleases fused to deaminases, optionally in complex with guide RNAs. Compositions also include nucleic acid molecules encoding the deaminases or the fusion proteins. Vectors and host cells comprising the nucleic acid molecules encoding the deaminases or the fusion proteins are also provided.Type: GrantFiled: September 1, 2022Date of Patent: May 14, 2024Assignee: LifeEDIT Therapeutics, Inc.Inventors: Tyson D. Bowen, Alexandra Briner Crawley, Tedd D. Elich
-
Patent number: 11981916Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: GrantFiled: September 1, 2022Date of Patent: May 14, 2024Assignee: LifeEDIT Therapeutics, Inc.Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
-
Patent number: 11926843Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: GrantFiled: September 17, 2021Date of Patent: March 12, 2024Assignee: LifeEDIT Therapeutics, Inc.Inventors: Alexandra Briner Crawley, Rodolphe Barrangou, Tyson D. Bowen, Michael Coyle, Tedd D. Elich
-
Publication number: 20240026384Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: August 10, 2023Publication date: January 25, 2024Applicant: LifeEDIT Therapeutics, Inc.Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
-
Patent number: 11859181Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: GrantFiled: August 31, 2022Date of Patent: January 2, 2024Assignee: LIFEEDIT THERAPEUTICS, INC.Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
-
Patent number: 11753651Abstract: The present invention is directed to methods and compositions comprising novel CRISPR polypeptides and polynucleotides for site-specific cleavage and nicking of nucleic acids, transcriptional control and genome editing.Type: GrantFiled: September 6, 2019Date of Patent: September 12, 2023Assignee: North Carolina State UniversityInventors: Rodolphe Barrangou, Alexandra Briner Crawley
-
Publication number: 20230272398Abstract: Compositions and methods for binding to a target sequence of interest are provided. Compositions include fusion proteins between DNA binding proteins or protein domains and nucleic acid modifying proteins or protein domains. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, deaminases, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs. Also provided are deaminases which may be fused to a DNA-binding polypeptide and may be useful for gene editing.Type: ApplicationFiled: May 12, 2023Publication date: August 31, 2023Applicant: LifeEDIT Therapeutics, Inc.Inventors: Tyson D. Bowen, Alexandra Briner Crawley, Tedd D. Elich, Mark Moore, Michael Lassner
-
Publication number: 20230257742Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: August 31, 2022Publication date: August 17, 2023Applicant: LifeEDIT Therapeutics, Inc.Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
-
Publication number: 20230235360Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: September 1, 2022Publication date: July 27, 2023Applicant: LifeEDIT Therapeutics, Inc.Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
-
Publication number: 20230203463Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, detecting a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: December 28, 2020Publication date: June 29, 2023Applicant: LifeEDIT Therapeutics, Inc.Inventors: Alexandra Briner Crawley, Philip Borden, Tyson D. Bowen, Michael Coyle, Madison R. Rackear, Tedd D. Elich
-
Publication number: 20230175018Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease (RGN) polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are RGN systems for binding a target sequence of interest, wherein the RGN system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: June 28, 2022Publication date: June 8, 2023Applicant: LifeEDIT Therapeutics, Inc.Inventors: Tyson D. Bowen, Michael Coyle, Alexandra Briner Crawley, Tedd D. Elich
-
Publication number: 20230002747Abstract: Compositions and methods comprising novel deaminase polypeptides for targeted editing of nucleic acids are provided. Compositions comprise deaminase polypeptides. Also provided are fusion proteins comprising a DNA-binding polypeptide and a deaminase of the invention. The fusion proteins include RNA-guided nucleases fused to deaminases, optionally in complex with guide RNAs. Compositions also include nucleic acid molecules encoding the deaminases or the fusion proteins. Vectors and host cells comprising the nucleic acid molecules encoding the deaminases or the fusion proteins are also provided.Type: ApplicationFiled: September 1, 2022Publication date: January 5, 2023Applicant: LifeEDIT Therapeutics, Inc.Inventors: Tyson D. Bowen, Alexandra Briner Crawley, Tedd D. Elich
-
Publication number: 20220364074Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs. Methods and kits for detecting a target DNA sequence are also provided.Type: ApplicationFiled: August 11, 2020Publication date: November 17, 2022Applicant: LIFEEDIT THERAPEUTICS, INC.Inventors: Tyson D. Bowen, Alexandra Briner Crawley, Tedd D. Elich, Michael Coyle
-
Patent number: 11499169Abstract: The present invention is directed to methods and compositions for typing of Lactobacillus buchneri bacterial strains, detecting the presence of a L. buchneri in a sample, identifying a strain of L. buchneri having resistance to an invasive foreign genetic element, modifying the resistance of bacteria and archeae to an invasive foreign genetic element, and introducing nicks into or cleaving double stranded DNA for genome editing.Type: GrantFiled: January 28, 2020Date of Patent: November 15, 2022Assignee: North Carolina State UniversityInventors: Rodolphe Barrangou, Alexandra Briner Crawley
-
Publication number: 20220348894Abstract: Compositions and methods comprising novel deaminase polypeptides for targeted editing of nucleic acids are provided. Compositions comprise deaminase polypeptides. Also provided are fusion proteins comprising a DNA-binding polypeptide and a deaminase of the invention. The fusion proteins include RNA-guided nucleases fused to deaminases, optionally in complex with guide RNAs. Compositions also include nucleic acid molecules encoding the deaminases or the fusion proteins. Vectors and host cells comprising the nucleic acid molecules encoding the deaminases or the fusion proteins are also provided.Type: ApplicationFiled: June 28, 2022Publication date: November 3, 2022Applicant: LifeEDIT Therapeutics, Inc.Inventors: Tyson D. Bowen, Alexandra Briner Crawley, Tedd D. Elich
-
Publication number: 20220145296Abstract: Compositions and methods for binding to a target sequence of interest are provided. Compositions include fusion proteins between DNA binding proteins or protein domains and nucleic acid modifying proteins or protein domains. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, deaminases, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs. Also provided are deaminases which may be fused to a DNA-binding polypeptide and may be useful for gene editing.Type: ApplicationFiled: December 20, 2019Publication date: May 12, 2022Applicant: LifeEDIT Therapeutics, Inc.Inventors: Tyson D. Bowen, Alexandra Briner Crawley, Tedd D. Elich, Mark Moore, Rodolphe Barrangou, Michael Lassner
-
Publication number: 20220002756Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: ApplicationFiled: September 17, 2021Publication date: January 6, 2022Applicant: LifeEDIT Therapeutics, Inc.Inventors: Alexandra Briner Crawley, Rodolphe Barrangou, Tyson D. Bowen, Michael Coyle, Tedd D. Elich
-
Patent number: 11162114Abstract: Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.Type: GrantFiled: June 5, 2019Date of Patent: November 2, 2021Assignee: LifeEDIT Therapeutics, Inc.Inventors: Alexandra Briner Crawley, Rodolphe Barrangou, Tyson D. Bowen, Michael Coyle, Tedd D. Elich
-
Publication number: 20210172008Abstract: Compositions and methods for isolating new variants of known clustered regularly-interspaced short palindromic repeat (CRISPR) RNA-guided nuclease (RGN) genes and new CRISPR systems are provided. The methods find use in identifying CRISPR RGN gene variants in complex mixtures. Compositions comprise hybridization baits that hybridize to CRISPR RGN genes of interest in order to selectively enrich variant polynucleotides from complex mixtures. Bait sequences may be specific for a number of CRISPR RGN genes from distinct gene families of interest and may be designed to cover each CRISPR RGN gene of interest by at least 2-fold. Bait pools may also comprise baits for sequences flanking CRISPR RGN genes of interest to allow for the identification of tracrRNAs corresponding to novel CRISPR RGN variants and a complete CRISPR system comprising a CRISPR RGN and its associated guide RNA.Type: ApplicationFiled: April 3, 2019Publication date: June 10, 2021Applicant: LIFEEDIT, Inc.Inventors: Alexandra Briner Crawley, James R. Henriksen, Mark Moore, Rebecca E. Thayer
-
Publication number: 20210017507Abstract: The present invention is directed to methods and compositions for genome editing and DNA targeting of proteins.Type: ApplicationFiled: August 25, 2020Publication date: January 21, 2021Inventors: Rodolphe Barrangou, Kurt M. Selle, Alexandra Briner Crawley